DOI: 10.36347/sajp.2020.v09i02.007

Pages: 90-94

Obesity is a chronic disease, it is the result of multiple causes, which is why medications have now appeared for treatment, and some have been withdrawn due to serious adverse events; In Colombia there are two drugs approved with the indication of obesity. These are: orlistat and liraglutide. We present the clinical case of a 78-year-old patient with a history of obesity and hypertriglyceridemia, who started with cholestasis and renal failure, where when doing the clinical analysis, rule out organic causes and herbal toxicity; It was concluded with the clinical, biopsy and analysis of adverse reactions that the hepatotoxicity was given by orlistat, which was started 3 months before, after suspending she present an initial increase in transaminases with subsequent good clinical and paraclinical evolution, both hepatic and renal.